As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against its competitors. | As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ...

Novartis has made radiopharma one of the pillars of its business, adding Lutathera through the AAA acquisition and Pluvicto via its $2.1 billion purchase of Endocyte in 2019, whilst growing its ...

The advent of targeted radiopharmaceuticals is revolutionising the field of oncology. These innovative therapies integrate systemically delivered radiotherapy into diagnostic and personalised ...

The government payor said it will separately pay for specialized diagnostic radiopharmaceuticals without transitional pass-through payment status.

Patients with prostate cancer may differ in time to testosterone recovery, depending on the length of treatment and age, but takes six months on average. It’s crucial for patients with prostate cancer ...